dydrogesterone / Generic mfg. - LARVOL DELTA

Comparing Dydrogesterone Versus Medroxyprogesterone in Progestin-Primed Ovarian Stimulation (PPOS) for Patients Undergoing In Vitro Fertilization/Intracytoplasmic Sperm Injection: A Systematic Review. (PubMed, Cureus) - "These findings indicate that both DYG and MPA are effective and safe for LH surge suppression in PPOS protocols, with DYG potentially offering a more physiologic hormonal profile and reduced gonadotropin use. Further randomized controlled trials are recommended to validate these results."

Journal • Preclinical • Review • Gynecology

Comment on: Fewer good-quality cleavage embryos in dydrogesterone-primed ovarian stimulation compared to GnRH antagonist protocol in POSEIDON group 4 patients. (PubMed, J Formos Med Assoc) - No abstract available

Journal

Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET (clinicaltrials.gov) - P3 | N=716 | Recruiting | Sponsor: The University of Hong Kong | Trial completion date: Nov 2025 ➔ Nov 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Infertility

Reply: Fetal safety of dydrogesterone: clarifying the role of pharmacovigilance. (PubMed, Hum Reprod Open) - No abstract available

Adverse events • Journal

Why does the latest pharmacovigilance data not reflect clinical experience with dydrogesterone? (PubMed, Hum Reprod Open) - No abstract available

Adverse events • Journal

Long-Term Outcomes of Dydrogesterone in Postoperative Endometriosis：A Real-World Study (ChiCTR) - P=N/A | N=332 | Not yet recruiting | Sponsor: Women’s Hospital, Zhejiang University School of Medicine; Women’s Hospital, Zhejiang University School of Medicine

New trial • Real-world evidence • Endometriosis • Gynecology • Women's Health

To explore the mechanism of acupuncture intervention on insulin resistance of phlegm-dampness polycystic ovary syndrome based on oxidative homeostasis (ChiCTR) - P=N/A | N=66 | Recruiting | Sponsor: Fujian Maternal and Child Health Care Hospital; Fujian Maternal and Child Health Care Hospital

New trial • Polycystic Ovary Syndrome

Ovarian Responses and Outcomes of In Vitro Fertilization Following Progesterone-Primed Ovarian Stimulation and Gonadotropin-Releasing Hormone (GnRH) Antagonist Protocols Using Follitropin Delta. (PubMed, Cureus) - "Both the GnRH antagonist and PPOS protocols demonstrated trends toward higher numbers of retrieved oocytes and blastocysts, with comparable pregnancy rates across all age groups, suggesting similar clinical outcomes. A key limitation of this study is its retrospective design at a single institution; therefore, future prospective, large-scale studies are warranted."

Journal • Preclinical • Endometriosis • Gynecology • Infertility • Women's Health

Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF (clinicaltrials.gov) - P=N/A | N=220 | Terminated | Sponsor: ShangHai Ji Ai Genetics & IVF Institute | N=784 ➔ 220 | Trial completion date: Dec 2025 ➔ May 2025 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2024 ➔ May 2025; The study was terminated due to difficulty in recruiting patients.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Gynecology • Infertility • Sexual Disorders

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A (clinicaltrials.gov) - P3 | N=400 | Completed | Sponsor: ShangHai Ji Ai Genetics & IVF Institute | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ May 2025

Trial completion • Trial completion date

Effects of kuntai capsule in combination with hormone replacement therapy on premature ovarian failure and bone metabolism. (PubMed, Afr J Reprod Health) - "A total of 190 POF patients were randomly assigned to either a control group (n=95) receiving HRT alone (1 mg estradiol valerate tablets and 10 mg dydrogesterone tablets), or an observation group (n=95) receiving a combination of HRT and Kuntai Capsule. The observation group also had a significantly lower recurrence rate (7.3%) after 24 months, compared to the control group (16.8%). These results suggest that the combination of Kuntai Capsule and HRT offers a promising treatment for POF, improving ovarian function, hormone levels, and bone health while reducing recurrence risk."

Clinical • Journal • Women's Health

Comprehensive Review of Hormone Therapy in Menopause: Cardiovascular and Metabolic Impacts in Women with Obesity (ECO 2025) - "A randomized control trial on CEE combined with natural progesterone or dydrogesterone demonstrated significant improvements in HDL-C and LDL-C levels, but increased triglyceride concentrations (p = 0.140), especially at higher doses. Hormone therapy in women with obesity in postmenopause demonstrated a wide range of metabolic and cardiovascular effects, with significant variations depending on the type, dose, and method of administration of hormonal agents. Low-dose transdermal estradiol offers a favorable safety profile for improving vascular function, with minimal inflammatory risks. On the other hand, the use of CEE, although beneficial for lipid profiles, requires caution due to the potential to exacerbate hypertriglyceridemia."

Clinical • Review • Cardiovascular • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Obesity

Treatment of Endometriosis – Focus on Improving Quality of Life (WCE 2025) - "The use of progestogens with affinity for receptors other than progesterone can lead to the development of side effects. In the presence of risks of endometriosis-associated complications, switching to dydrogesterone is recommended, since the presence of only a continuous regimen in dienogest limits its capabilities in terms of overcoming several undesirable effects. Group 2 patients were more likely to have endocrine and neurological diseases, which could possibly have influenced the occurrence of side effects and the need for early discontinuation of dienogest therapy."

HEOR • CNS Disorders • Depression • Endometriosis • Gynecology • Migraine • Pain • Psychiatry • Women's Health

Observational Open-Label Multicenter Study to Evaluate the Effects of Hormonal Therapy of Endometriosis: Stage 3-4 (the ORCHIDEA Study Subanalysis) (WCE 2025) - "Conclusion Based on the results of the study, it can be concluded that dydrogesterone is highly effective in the treatment of stage III-IV endometriosis. Prolonged cyclic and continuous treatment regimens have similar effectiveness in reducing chronic pelvic pain, improving quality of life and sexual well-being."

Clinical • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Dydrogesterone for Treatment of Chronic Pelvic Pain Associated with Endometriosis and Reproductive Outcomes: A Systematic Review and Meta-analysis (WCE 2025) - "Conclusion The results demonstrate a significative prevalence (81 and 89%) of improvement on pelvic pain with the use of dydrogesterone treatment (cyclical or continuous) respectively in women with endometriosis and a success in achieving pregnancy in 17% of patients during or after its use. Key-words: endometriosis; dydrogesterone; pregnancy"

Retrospective data • Review • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

Macrophage membraneencapsulated dydrogesterone nanocrystal delivery system: a new strategy for improving the progression of adenomyosis via inhibiting inflammation in uterus (ASRI 2025) - "In this study, we firstly developed a biomimetic nanoparticle using dydrogesteron that efficiently and safely inhibits the progression of adenomyosis. The successful preparation of dydrogesterone nanocrystallization involved encapsulating DG-NPs by MM, which effectively evades phagocytosis by macrophages. This innovative approach integrates the distinct advantages of nanocrystalline drug formulation with the targeted delivery capabilities of macrophage membrane encapsulation, establishing a novel therapeutic paradigm for managing adenomyosis, a complex gynecological disorder."

Endometriosis • Gynecology • Infertility • Inflammation • Musculoskeletal Pain • Pain • Sexual Disorders • Women's Health • IFNG • IL6 • TNFA

Optimizing Ovarian Stimulation in High LH Patients: Can Targeted LH Regulation Improve Oocyte Yield, Blastulation, and Euploid Embryo Rates? (ASRI 2025) - "Patients with high baseline LH levels and poor previous stimulation outcomes may benefit from LH regulation strategies using dydrogesterone. The balance between suppression and LH sufficiency is crucial to achieving optimal follicular response. Strengthening pituitary suppression without excessive LH reduction (< 1 mIU/mL) appears to enhance oocyte yield and embryo quality."

Clinical • Infertility • Polycystic Ovary Syndrome • Sexual Disorders

Oral dydrogesterone versus oral dydrogesterone plus micronized vaginal progesterone for luteal phase support in ovulatory frozen-thawed embryo transfers. (PubMed, Reprod Biomed Online) - "Oral DYD alone is comparable to DYD + MVP for LPS in ovulatory FET cycles in terms of pregnancy and neonatal outcomes."

Journal

Composition for Treating Uterine Fibroid (SB-UF) (clinicaltrials.gov) - P4 | N=66 | Completed | Sponsor: Trieu, Nguyen Thi, M.D. | Phase classification: P=N/A ➔ P4

Phase classification • Gynecology • Solid Tumor • Uterine Leiomyoma • Women's Health

Disproportionality analysis of progestogens and estrogens demonstrates increased meningioma risk. (PubMed, J Clin Neurosci) - "The study reveals significant variations in meningioma risk associated with different hormonal therapies. Certain progestogens and estrogens present notably higher risks, emphasizing the need for personalized risk assessments in hormonal therapy prescriptions. These findings advocate for further research to better understand meningioma risk linked to hormone-based contraceptives, supporting safer clinical decision-making."

Journal • Brain Cancer • Meningioma • Oncology • Solid Tumor • ROR1

Progestogens in Menopausal Hormone Therapy: A Double-Edged Sword. (PubMed, Semin Reprod Med) - "Progestogens (norethisterone acetate, medroxyprogesterone acetate, dydrogesterone, micronized progesterone, levonorgestrel, drospirenone, and trimegestone) added to estrogen for endometrial protection are reviewed. In conclusion, progestogens are a double-edged sword, effectively protecting the endometrium but causing several side effects and reducing many estrogen-induced benefits. With modern endometrial diagnostic tools, the safety of low-dose unopposed estrogen regimens should be assessed in a prospective controlled trial in women with an intact uterus."

Journal • Alzheimer's Disease • Breast Cancer • Cardiovascular • CNS Disorders • Colorectal Cancer • Dementia • Hematological Disorders • Long-acting Reversible Contraceptives • Oncology • Solid Tumor • Thrombosis

Comparison of the euploidy rate in preimplantation genetic testing for aneuploidy cycles following progestin-primed versus gonadotropin-releasing hormone antagonist protocol: a randomized controlled study. (PubMed, Reprod Biol Endocrinol) - P=N/A | "Both PPOS and antagonist protocols had similar euploidy rates in PGT-A cycles."

Clinical • Journal • Infertility

Oral Dydrogesterone Versus Vaginal Progesterone for Luteal Phase Support in Frozen-Thawed Embryo Transfer Cycles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, J Clin Med) - "Given its ease of administration, dydrogesterone may serve as a viable alternative in future FET protocols. However, further RCTs are needed to assess its efficacy against other progesterone administration routes."

Journal • Retrospective data • Review • Gynecology

Progestin-primed ovarian stimulation for oocyte cryopreservation in patients with nonmedical indications: a case-control study. (PubMed, Reprod Biol Endocrinol) - "The response to ovarian stimulation with the PPOS protocol for oocyte cryopreservation in patients with nonmedical indications does not differ statistically from that with the antagonist protocol in terms of the number of MII oocytes. This protocol offers the advantages of a more patient-friendly approach through oral administration, a significantly lower number of monitoring sessions with the same efficacy as the antagonist protocol and could be offered as a first line treatment."

Journal

Dydrogesterone for preventing endometrial polyp recurrence after transcervical resection of polyps: protocol for a multicentre randomised controlled trial in China. (PubMed, BMJ Open) - P=N/A | "The study findings will be published in peer-reviewed journals and presented at academic conferences. ChiCTR2400083097."

Journal • Gynecology • Women's Health